We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Folic Acid and Omega -3 Fatty Acid Supplementation in Depressed Older Adults

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00480207
First Posted: May 30, 2007
Last Update Posted: November 6, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
The S. Daniel Abraham International Center for Health and Nutrition
Information provided by (Responsible Party):
Prof. RH Belmaker, Beersheva Mental Health Center
  Purpose
Our specific aim is to determine the impact of folic acid and omega-3 supplementation on the severity of depressive symptoms among depressed adults aged 65 and above.

Condition Intervention Phase
Depression Dietary Supplement: folic acid Dietary Supplement: omega-3 Dietary Supplement: vit B12 Other: folic acid placebo Other: omega-3 placebo Phase 2 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Outcomes Assessor)
Primary Purpose: Supportive Care
Official Title: Randomized Double-blind Controlled Clinical Trial to Assess the Impact of Folic Acid and Omega-3 Fatty Acids Supplementation on the Severity of Depressive Symptoms in Older Adults With Identified Depression

Resource links provided by NLM:


Further study details as provided by Prof. RH Belmaker, Beersheva Mental Health Center:

Primary Outcome Measures:
  • the severity of depressive symptoms [ Time Frame: baseline, 4th , 8th and 12th week ]

Secondary Outcome Measures:
  • cognitive status [ Time Frame: baseline, 4th, 8th, and 12th week ]
  • nutritional status [ Time Frame: baseline and end of study ]
  • possible side effects [ Time Frame: baseline, 4th, 8th, and 12th week ]

Enrollment: 15
Study Start Date: May 2007
Study Completion Date: October 2008
Primary Completion Date: October 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: omega-3, folic acid, vitB12
folic acid (1600 mcg per day), and omega-3 (2000 mg per day: active docosahexaenoic acid (DHA) and eicosapentanoic acid (EPA), proportion 1:1), vitamin B12 (1000 mcg per day)
Dietary Supplement: folic acid Dietary Supplement: omega-3 Dietary Supplement: vit B12
Experimental: omega-3, folic acid placebo, vit B12
omega-3,folic acid placebo (starch), vitamin B12 (1000 mcg per day)
Dietary Supplement: omega-3 Dietary Supplement: vit B12 Other: folic acid placebo
Experimental: omega-3 placebo, folic acid, vit B12
folic acid, omega-3 placebo(canola oil),vitamin B12 (1000 mcg per day)
Dietary Supplement: folic acid Dietary Supplement: vit B12 Other: omega-3 placebo
Experimental: omega-3 placebo, folic acid placebo, vit B12
omega-3 placebo (canola oil),folic acid placebo (starch), vitamin B12 (1000 mcg per day)
Dietary Supplement: vit B12 Other: folic acid placebo Other: omega-3 placebo

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   65 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age 65+ (year of birth -1942 or below)
  2. Depression (as defined by the DSM-IV diagnostic criteria for depression: major or minor depression or dysthymia)

Exclusion Criteria:

  1. Co-existing psychiatric disorder (except anxiety disorders)
  2. Moderate and severe cognitive impairment
  3. Current treatment with anticoagulants, antithrombotics and fibrinolytics
  4. Current severe angina with exertion
  5. Chronic renal insufficiency
  6. Liver cirrhosis
  7. Alcohol or drug abuse
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00480207


Locations
Israel
Mental Health Center
Beer-Sheva, Israel
Sponsors and Collaborators
Prof. RH Belmaker
The S. Daniel Abraham International Center for Health and Nutrition
Investigators
Study Director: Danit R Shahar, RD PhD Ben-Gurion University of the Negev
Principal Investigator: Alex Palatnik, MD Beersheva Mental Health Center
Principal Investigator: Larissa German, MD, MMedSc The S. Daniel Abraham International Center for Health and Nutrition
  More Information

Responsible Party: Prof. RH Belmaker, Beersheva Mental Health Center
ClinicalTrials.gov Identifier: NCT00480207     History of Changes
Other Study ID Numbers: ICHN-4413
First Submitted: May 28, 2007
First Posted: May 30, 2007
Last Update Posted: November 6, 2012
Last Verified: November 2012

Additional relevant MeSH terms:
Depression
Depressive Disorder
Behavioral Symptoms
Mood Disorders
Mental Disorders
Folic Acid
Hydroxocobalamin
Vitamin B Complex
Vitamin B 12
Hematinics
Vitamins
Micronutrients
Growth Substances
Physiological Effects of Drugs